FABP4 and metabolic syndrome: Treatment with omega-3 fatty acid ethyl esters containing EPA and DHA decreases serum FABP4 concentration in patients with dyslipidemia, at least in part, via a direct reduction in expression and consecutive secretion of FABP4 in adipocytes.